UPDATE: Piper Jaffray Raises Price Target on Abiomed to $27

According to Piper Jaffray, Abiomed

price target is raised to $27. Piper Jaffray said that the Street was looking for a big quarter, and ABMD delivered. “Robust Impella sales were driven by 44% US growth (43% globally) as physician adoption accelerates on the back of recent SCAI guidelines.” Abiomed closed yesterday at $23.22.